PubMed ID: 37756673
Author(s): Elnahry AG, Bellur S, Wiley HE, Sen HN, Kodati S. Treatment of Intermediate Uveitis-associated Retinal Vasoproliferative Tumors: A Case Series. Retin Cases Brief Rep. 2023 Sep 19. doi: 10.1097/ICB.0000000000001494. Online ahead of print. PMID 37756673
Journal: Retinal Cases & Brief Reports, Sep 2023
PURPOSE To report the use of combination intravitreal pharmacotherapy using anti-vascular endothelial growth factor (VEGF) and short and long-term corticosteroid implants for the treatment of retinal vasoproliferative tumors (VPT) associated with intermediate uveitis.
METHODS Retrospective chart review of patients with VPT secondary to idiopathic intermediate uveitis that underwent combination intravitreal pharmacotherapy at a single center was performed. Multimodal imaging including ultrawide field color fundus photography, ultrawide field fluorescein angiography, and optical coherence tomography obtained before and after treatment were reviewed.
RESULTS Four eyes of 4 patients were treated with multiple injections of a combination of aflibercept, dexamethasone, and fluocinolone acetonide implants for VPT associated with intermediate uveitis. All 4 patients had improvement in visual acuity, intraocular inflammation, central macular thickness, and retinal vascular leakage, as well as regression of the VPT and reduction in lesion leakage on follow-up.
CONCLUSION Combination intravitreal anti-VEGF and corticosteroid implants may be a useful approach for the treatment of intermediate uveitis-associated VPTs and can lead to both functional and structural improvement.